Rush University Cancer Center
Rush University Cancer Center
Chicago, Illinois, United States4 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, metastatic prostate carcinoma, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 2 | 2026-06-01 | NCT03012321 | |
| A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), brain disorder, central nervous system cancer, central nervous system disorder, epithelial neoplasm, glioblastoma, glioma, neoplasm, nervous system disorder, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 2 | 2026-04-15 | NCT04762069 | |
| Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 | Disease Attributes, Disease Progression, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 3 | 2025-10-01 | NCT04229979 | |
| Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 1 / Phase 2 | 2025-06-17 | NCT02843945 |